Issue 1 - San Antonio Breast Cancer Symposium

More documents

Recommendations

Info

14 Plenary Lectures to Address Epidemiology, Molecular Biology, Immunology Each day of the SABCS traditionally begins with a plenary lecture featuring a world-renowned researcher presenting a definitive update on his or her field of interest. This year is no exception, with invited speakers who offer a very good reason to get up early each morning. On Thursday morning at 8:45 am, Valerie Beral, MD, will speak on An Epidemiological Perspective on the Causes and Prevention of Breast Cancer. Dr Beral is the director of the Cancer Epidemiology Unit and a professor of epidemiology at the University of Oxford. Her research has focused on the role of reproductive, hormonal, and infectious agents in cancer. She is principal investigator for the Million Women Study, the largest study in the world investigating how a woman’s reproductive history can affect her health. On Friday at 9:00 am, William Sellers, MD, will discuss the role of the PI3K/Akt/mTOR pathway in cancer. Dr Sellers is currently the vice president and global head of oncology for the Novartis Institute of BioMedical Research in Cambridge, Massachusetts. mTOR is a cytoplasmic protein kinase that acts as a central regulator in cell proliferation, angiogenesis, and cell metabolism. It represents an exciting potential therapeutic target because it is a key intracellular point of convergence for many important signaling pathways located upstream from it. These pathways can be activated by various signaling proteins, including cell surface growth factor receptors such as VEGFR, a number of which are abnormally activated in cancer. Tyler Curiel, MD, will speak on Saturday at 9:00 am, assessing new paradigms in cancer immunology. Dr Curiel is the former executive director of the Cancer Therapy & Research Center at the University of Texas Health Science Center at San Antonio. In a landmark paper published in Nature Medicine in 2004, Dr Curiel and his team made the first definitive identification of an “off switch” in human cancer, the specific recruitment of regulatory T cells to mediate the suppression of tumorassociated antigen-reactive lymphocytes. He is considered one of the leading researchers in the study of immunopathological mechanisms in human cancer.
Issue 1, December 10, 2009 Supporters We are proud to acknowledge the following for their contributions to and generous support of our program (at press time). ANGEL PLUS Abraxis Bioscience Genentech BioOncology GlaxoSmithKline Lilly USA, LLC Novartis Oncology sanofi-aventis ANGEL Genomic Health, Inc. Pfizer PATRON PLUS Amgen AstraZeneca Bristol-Myers Squibb Merck Oncology MAJOR SUPPORTER PLUS Wyeth Pharmaceuticals MAJOR SUPPORTER Monogram Biosciences Onyx CONTRIBUTOR bioTheranostics, Inc. Carl Zeiss Meditec, Inc. Eisai, Inc. EMD Serono Halo Breast Pap Test (Neomatrix) HistoRx Imclone Systems IOS Press CONTRIBUTOR (continued) Ipsogen Myriad Genetic Laboratories, Inc. Research To Practice SenoRx Ventana Medical Systems, Inc. A Member of the Roche Group DONOR Agendia, Inc. American Express OPEN AmeriPath, Inc. Amoena USA Corporation Aurora Imaging Technology, Inc. Biocare Medical Biopsy Sciences Caris Diagnostics Clarient, Inc. Clinical Care Options Clinical Oncology News Combimatrix Molecular Diagnostics CuraScript CVS Caremark/CarePlus Cytori Therapeutics, Inc. Dako North America, Inc. deCODE genetics Diplomat Specialty Pharmacy DXS Ltd Endomagnetics Ltd Faxitron X-Ray LLC Gamma Medica-Ideas Hologic ImpediMed, Inc Informed Medical Decisions, Inc. SABCS gratefully acknowledges Susan G. Komen for the Cure® for generous support of AACR Outstanding Investigator Award for Breast Cancer Research , CTCR-AACR San Antonio Breast Cancer Symposium Educational Sessions, AACR Translational Research Scholars, and Minority Scholar Awards for Breast Cancer Research. SABCS wishes to thank Avon Foundation for support of the Avon Foundation-AACR International Scholar-In-Training Grants. DONOR (continued) IntraOp Medical Corporation Leica Microsystems Lippincott Williams & Wilkins Medtronic Milestone Onco Inc. Patient Advocate Foundation PhenoPath Laboratories, PLLC Physicians’ Education Resource PRIME Oncology R&D Systems, Inc. RadPharm, Inc. Siemens Healthcare Diagnostics Springer Sysmex America, Inc. US Labs US Oncology Varian Medical Systems Xceed Molecular CONFERENCE GRANTS American Cancer Society, Texas Division National Cancer Institute SERvICE IN kIND Adjuvant, Inc. AlphaMed Press/The Oncologist Elsevier Inter-American Breast Cancer Conference The Oncology Group 15
Page 1 and 2: 1 Issue 1 December 10, 2009 “An i
Page 3 and 4: Speaker & Schedule Changes Thursday
Page 5 and 6: Abstract 112 Prediction of 10-year
Page 7 and 8: Abstract 41 PL + D (n=241) BV 7.5 m
Page 9 and 10: Abstract 710 A phase 2 study of tra
Page 11 and 12: SABCS Scholarship Recipients This y
Page 13: Issue 1, December 10, 2009 Brinker

Issue 1 - San Antonio Breast Cancer Symposium

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?